A CXCR4 Inhibitor (Balixafortide) Enhances Docetaxel-Mediated Antitumor Activity in a Murine Model of Prostate Cancer Bone Metastasis

PC-3 luciferase-labeled cells were injected into the tibia of mice to model bone metastases. Four treatment groups were created: vehicle, docetaxel (5 mg/kg), balixafortide (20 mg/kg), and combination of both.